DK3200815T3 - Fremgangsmåder og sammensætninger til behandling af cancer - Google Patents

Fremgangsmåder og sammensætninger til behandling af cancer Download PDF

Info

Publication number: DK3200815T3
Authority: DK; Denmark
Prior art keywords: compositions; methods; treating cancer; cancer; treating
Prior art date: 2014-10-02

Application number

DK15847792.7T

Other languages

English (en)

Inventor

Jose R Conejo-Garcia

Alfredo Perales-Puchalt

Original Assignee

Wistar Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-02

Filing date

2015-09-30

Publication date

2021-05-10

2015-09-30 Application filed by Wistar Inst filed Critical Wistar Inst

2021-05-10 Application granted granted Critical

2021-05-10 Publication of DK3200815T3 publication Critical patent/DK3200815T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)

DK15847792.7T 2014-10-02 2015-09-30 Fremgangsmåder og sammensætninger til behandling af cancer DK3200815T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462059068P	2014-10-02	2014-10-02
US201562202824P	2015-08-08	2015-08-08
PCT/US2015/053128 WO2016054153A1 (en)	2014-10-02	2015-09-30	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
DK3200815T3 true DK3200815T3 (da)	2021-05-10

Family

ID=55631412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15847792.7T DK3200815T3 (da)	2014-10-02	2015-09-30	Fremgangsmåder og sammensætninger til behandling af cancer

Country Status (16)

Country	Link
US (4)	US10259855B2 (da)
EP (1)	EP3200815B1 (da)
CN (2)	CN114150018A (da)
CA (1)	CA2989807C (da)
CY (1)	CY1125797T1 (da)
DK (1)	DK3200815T3 (da)
ES (1)	ES2870607T3 (da)
HR (1)	HRP20210705T1 (da)
HU (1)	HUE054673T2 (da)
LT (1)	LT3200815T (da)
PL (1)	PL3200815T3 (da)
PT (1)	PT3200815T (da)
RS (1)	RS61929B1 (da)
SI (1)	SI3200815T1 (da)
SM (1)	SMT202100273T1 (da)
WO (1)	WO2016054153A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016073456A1 (en) *	2014-11-04	2016-05-12	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
CN108883181A (zh) *	2016-04-05	2018-11-23	葛兰素史密斯克莱知识产权发展有限公司	在免疫疗法中抑制TGFβ
KR102636093B1 (ko) *	2016-10-11	2024-02-13	온코그린 테라퓨틱스 에스아	종양의 진단 및 치료에서 fsh 호르몬 수용체의 리간드
IT201600101852A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
IT201600101870A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
US12485102B2 (en)	2017-08-02	2025-12-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for treating cancer
WO2019046540A1 (en)	2017-08-31	2019-03-07	New York Genome Center, Inc.	METHODS AND COMPOSITIONS COMPRISING CRISPR-CPF1 AND APPROVED GUIDING CRISPR RNAES FOR PROGRAMMABLE GENOMIC DELETIONS
WO2019070740A2 (en) *	2017-10-02	2019-04-11	Fred Hutchinson Cancer Research Center	LUTENING HORMONE RECEPTOR BINDING AGENTS AND LUTINISING HORMONE AGONISTS FOR IDENTIFICATION, MULTIPLICATION, REMOVAL AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
JP2021509903A (ja) *	2018-01-05	2021-04-08	マックスサイトインコーポレーティッド	癌の長期ｃａｒ処置
WO2020033797A1 (en)	2018-08-09	2020-02-13	The Wistar Institute	Anti-follicule stimulating hormone receptor antibodies
WO2020095113A1 (en) *	2018-11-05	2020-05-14	Ludwig Institute For Cancer Research Ltd	Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
WO2020146233A1 (en) *	2019-01-07	2020-07-16	H. Lee Moffitt Cancer Center And Research Institute Inc.	Foxp1-ablated chimeric cells
WO2020160310A1 (en) *	2019-01-30	2020-08-06	The Wistar Institute Of Anatomy And Biology	Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
WO2020210774A1 (en) *	2019-04-12	2020-10-15	Emory University	Compositions and methods for promoting hematopoietic cell cytotoxicity
WO2021168421A1 (en) *	2020-02-20	2021-08-26	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Method of enhancing immunotherapy using er stress pathway inhibitors
WO2022174052A1 (en) *	2021-02-12	2022-08-18	The Wistar Institute Of Anatomy And Biology	Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) *	2023-02-07	2023-12-01	徐州医科大学	利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5702702A (en)	1992-03-30	1997-12-30	The Wistar Institute Of Anatomy And Biology	Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
EP1453543B1 (en)	2001-11-21	2017-08-30	The Trustees Of The University Of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7081446B2 (en)	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
US20060247420A1 (en)	2002-09-04	2006-11-02	George Coukos	Immune cell recptor ligand and immune cell receptor
EP2000160A3 (en)	2002-10-30	2009-03-11	Gambro Lundia AB	Method and apparatuses for determining the efficiency of dialysis
ATE449105T1 (de)	2004-01-23	2009-12-15	Angeletti P Ist Richerche Bio	Impfstoffträger für schimpansen-adenovirus
CA2596711C (en)	2005-02-03	2015-12-15	Benitec, Inc.	Rnai expression constructs
GB0725201D0 (en) *	2007-12-24	2008-01-30	Asterion Ltd	Peptide fusion proteins
PT2252627T (pt)	2008-01-24	2017-07-24	Esperance Pharmaceuticals	Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
EP2090322A1 (en)	2008-02-18	2009-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fsh receptor ligands for diagnosis and therapy of cancer
EP2376109B1 (en) *	2008-12-19	2019-01-23	MacroGenics, Inc.	Covalent diabodies and uses thereof
PH12013501201A1 (en) *	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US9708384B2 (en)	2011-09-22	2017-07-18	The Trustees Of The University Of Pennsylvania	Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
WO2013063019A1 (en)	2011-10-28	2013-05-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
JP2016506373A (ja) *	2012-11-15	2016-03-03	エスペランスファーマシューティカルズ，インコーポレイテッド	卵胞刺激ホルモン（ｆｓｈ）／溶解ドメイン融合コンストラクト及びその作製及び使用の方法
CN103509121B (zh) *	2012-11-22	2015-01-28	苏州康宁杰瑞生物科技有限公司	一种fsh融合蛋白及其制备方法和用途
WO2016073456A1 (en)	2014-11-04	2016-05-12	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor

2015
- 2015-09-30 US US15/515,442 patent/US10259855B2/en active Active
- 2015-09-30 ES ES15847792T patent/ES2870607T3/es active Active
- 2015-09-30 HR HRP20210705TT patent/HRP20210705T1/hr unknown
- 2015-09-30 SI SI201531592T patent/SI3200815T1/sl unknown
- 2015-09-30 HU HUE15847792A patent/HUE054673T2/hu unknown
- 2015-09-30 RS RS20210553A patent/RS61929B1/sr unknown
- 2015-09-30 WO PCT/US2015/053128 patent/WO2016054153A1/en not_active Ceased
- 2015-09-30 CN CN202111464043.1A patent/CN114150018A/zh active Pending
- 2015-09-30 CN CN201580065382.9A patent/CN106999552B/zh active Active
- 2015-09-30 PT PT158477927T patent/PT3200815T/pt unknown
- 2015-09-30 EP EP15847792.7A patent/EP3200815B1/en active Active
- 2015-09-30 PL PL15847792T patent/PL3200815T3/pl unknown
- 2015-09-30 LT LTEP15847792.7T patent/LT3200815T/lt unknown
- 2015-09-30 DK DK15847792.7T patent/DK3200815T3/da active
- 2015-09-30 SM SM20210273T patent/SMT202100273T1/it unknown
- 2015-09-30 CA CA2989807A patent/CA2989807C/en active Active
2019
- 2019-02-21 US US16/281,472 patent/US11248033B2/en active Active
2021
- 2021-05-31 CY CY20211100466T patent/CY1125797T1/el unknown
- 2021-12-27 US US17/562,643 patent/US12384826B2/en active Active
2025
- 2025-07-15 US US19/269,573 patent/US20250340609A1/en active Pending

Also Published As

Publication number	Publication date
US12384826B2 (en)	2025-08-12
US20220185861A1 (en)	2022-06-16
US11248033B2 (en)	2022-02-15
CA2989807A1 (en)	2016-04-07
PT3200815T (pt)	2021-05-07
LT3200815T (lt)	2021-07-26
HRP20210705T1 (hr)	2021-07-23
CN106999552A (zh)	2017-08-01
HUE054673T2 (hu)	2021-09-28
EP3200815B1 (en)	2021-03-03
US20170226176A1 (en)	2017-08-10
SI3200815T1 (sl)	2021-11-30
CN106999552B (zh)	2021-12-28
CY1125797T1 (el)	2024-02-16
US10259855B2 (en)	2019-04-16
CN114150018A (zh)	2022-03-08
US20250340609A1 (en)	2025-11-06
PL3200815T3 (pl)	2021-10-18
EP3200815A4 (en)	2018-04-25
WO2016054153A1 (en)	2016-04-07
RS61929B1 (sr)	2021-06-30
US20190248862A1 (en)	2019-08-15
CA2989807C (en)	2023-07-04
ES2870607T3 (es)	2021-10-27
SMT202100273T1 (it)	2021-07-12
EP3200815A1 (en)	2017-08-09

Publication	Publication Date	Title
DK3245225T3 (da)	2021-10-18	Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3386518T3 (da)	2025-09-15	Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
IL255261A0 (en)	2017-12-31	Methods for treating cancer
DK3134130T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3888658T3 (da)	2024-03-18	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3125927T3 (da)	2021-04-19	Fremgangsmåder og sammensætninger til immunmodulering
DK3137605T3 (da)	2020-12-14	Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
BR112017011771A2 (pt)	2018-07-10	métodos e composições para o tratamento de câncer
DK2994533T3 (da)	2019-07-01	Fremgangsmåder og sammensætninger til behandling af cancer
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3206497T3 (da)	2020-12-21	Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3206493T3 (da)	2020-08-10	Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3215147T3 (da)	2024-04-02	Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3108009T3 (da)	2021-06-07	Fremgangsmåder og sammensætninger til DNA-profilering
DK3201351T3 (da)	2021-02-22	Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3377516T3 (da)	2022-09-19	Sammensætning til behandling af cancer
DK3204386T3 (da)	2021-05-25	Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
IL252182A0 (en)	2017-07-31	Method for treating cancer
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK2941258T3 (da)	2019-12-16	Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
HUE038541T2 (hu)	2018-10-29	Rák kezelési módszerek